PortfoliosLab logoPortfoliosLab logo
ELDN vs. BIIB
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ELDN vs. BIIB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eledon Pharmaceuticals Inc (ELDN) and Biogen Inc. (BIIB). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ELDN achieves a 131.13% return, which is significantly higher than BIIB's 11.35% return. Over the past 10 years, ELDN has underperformed BIIB with an annualized return of -43.86%, while BIIB has yielded a comparatively higher -3.85% annualized return.


ELDN

1D
-1.13%
1M
-7.67%
YTD
131.13%
6M
119.50%
1Y
10.09%
3Y*
21.83%
5Y*
-17.44%
10Y*
-43.86%

BIIB

1D
3.78%
1M
4.67%
YTD
11.35%
6M
8.41%
1Y
48.63%
3Y*
-13.25%
5Y*
-7.29%
10Y*
-3.85%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ELDN vs. BIIB - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ELDN
Eledon Pharmaceuticals Inc
131.13%-63.35%128.89%-21.05%-48.30%-71.36%47.51%-63.75%-60.59%-53.87%
BIIB
Biogen Inc.
11.35%15.09%-40.91%-6.55%15.42%-2.02%-17.48%-1.39%-5.54%12.34%

Correlation

The correlation between ELDN and BIIB is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (5Y)
Calculated over the trailing 5-year period

0.14

Correlation (10Y)
Calculated over the trailing 10-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Sep 18, 2014

0.14

Fundamentals

EPS

ELDN:

-$0.91

BIIB:

$12.48

Total Revenue (TTM)

ELDN:

$0.00

BIIB:

$9.86B

Gross Profit (TTM)

ELDN:

$0.00

BIIB:

$5.06B

EBITDA (TTM)

ELDN:

-$84.86M

BIIB:

$2.24B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Eledon Pharmaceuticals Inc

Biogen Inc.

Return for Risk

ELDN vs. BIIB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ELDN
ELDN Risk / Return Rank: 4848
Overall Rank
ELDN Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
ELDN Sortino Ratio Rank: 5050
Sortino Ratio Rank
ELDN Omega Ratio Rank: 5555
Omega Ratio Rank
ELDN Calmar Ratio Rank: 4444
Calmar Ratio Rank
ELDN Martin Ratio Rank: 4444
Martin Ratio Rank

BIIB
BIIB Risk / Return Rank: 8080
Overall Rank
BIIB Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
BIIB Sortino Ratio Rank: 7979
Sortino Ratio Rank
BIIB Omega Ratio Rank: 7474
Omega Ratio Rank
BIIB Calmar Ratio Rank: 8484
Calmar Ratio Rank
BIIB Martin Ratio Rank: 8484
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ELDN vs. BIIB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eledon Pharmaceuticals Inc (ELDN) and Biogen Inc. (BIIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ELDNBIIBDifference
Sharpe ratioReturn per unit of total volatility

-1.36

Sortino ratioReturn per unit of downside risk

-1.41

Omega ratioGain probability vs. loss probability

1.14

1.26

-0.12

Calmar ratioReturn relative to maximum drawdown

0.15

3.41

-3.26

Martin ratioReturn relative to average drawdown

0.27

8.35

-8.08

ELDN vs. BIIB - Sharpe Ratio Comparison

The current ELDN Sharpe Ratio is 0.11, which is lower than the BIIB Sharpe Ratio of 1.47. The chart below compares the historical Sharpe Ratios of ELDN and BIIB, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ELDNBIIBDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.11

1.47

-1.36

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.22

-0.19

-0.03

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.40

-0.09

-0.31

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.43

0.23

-0.66

Drawdowns

ELDN vs. BIIB - Drawdown Comparison

The maximum ELDN drawdown since its inception was -99.97%, which is greater than BIIB's maximum drawdown of -89.98%. Use the drawdown chart below to compare losses from any high point for ELDN and BIIB.


Loading charts...

Drawdown Indicators


ELDNBIIBDifference

Max Drawdown

Largest peak-to-trough decline

-99.97%

-89.98%

-9.99%

Max Drawdown (1Y)

Largest decline over 1 year

-68.12%

-14.34%

-53.78%

Max Drawdown (3Y)

Largest decline over 3 years

-73.77%

-63.82%

-9.95%

Max Drawdown (5Y)

Largest decline over 5 years

-87.69%

-72.66%

-15.03%

Max Drawdown (10Y)

Largest decline over 10 years

-99.90%

-72.66%

-27.24%

Current Drawdown

Current decline from peak

-99.91%

-58.83%

-41.08%

Average Drawdown

Average peak-to-trough decline

-92.00%

-36.60%

-55.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

37.47%

5.84%

+31.63%

Volatility

ELDN vs. BIIB - Volatility Comparison

Eledon Pharmaceuticals Inc (ELDN) has a higher volatility of 12.86% compared to Biogen Inc. (BIIB) at 9.88%. This indicates that ELDN's price experiences larger fluctuations and is considered to be riskier than BIIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ELDNBIIBDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.86%

9.88%

+2.98%

Volatility (6M)

Calculated over the trailing 6-month period

45.87%

24.17%

+21.70%

Volatility (1Y)

Calculated over the trailing 1-year period

89.49%

33.22%

+56.27%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

78.39%

38.45%

+39.94%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

110.23%

41.48%

+68.75%

Dividends

ELDN vs. BIIB - Dividend Comparison

Neither ELDN nor BIIB has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ELDN vs. BIIB - Financials Comparison

This section allows you to compare key financial metrics between Eledon Pharmaceuticals Inc and Biogen Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50B202220232024202520260
2.48B
(ELDN) Total Revenue
(BIIB) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ELDN and BIIB have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ELDN has higher volatility (12.86%) compared to BIIB (9.88%). In terms of maximum drawdown, ELDN dropped -99.97% vs BIIB's -89.98%.

BIIB currently has the higher Sharpe Ratio (1.47 vs 0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ELDN and BIIB

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer